Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-45,700
Closed -$15M 1442
2025
Q4
$15M Sell
45,700
-28,200
-38% -$8.95M 0.03% 256
2025
Q3
$20.9M Sell
73,900
-58,600
-44% -$17M 0.09% 170
2025
Q2
$37M Sell
132,500
-38,500
-23% -$10.9M 0.26% 78
2025
Q1
$53.3M Buy
171,000
+57,400
+51% +$16.9M 0.5% 34
2024
Q4
$29.6M Sell
113,600
-55,800
-33% -$16.6M 0.25% 81
2024
Q3
$54.6M Buy
169,400
+159,400
+1,594% +$52.1M 0.43% 38
2024
Q2
$3.12M Hold
10,000
0.03% 437
2024
Q1
$2.84M Sell
10,000
-89,700
-90% -$26.2M 0.03% 469
2023
Q4
$28.7M Hold
99,700
0.33% 64
2023
Q3
$26.8M Buy
99,700
+29,500
+42% +$7.36M 0.3% 71
2023
Q2
$15.6M Buy
+70,200
New +$16.3M 0.17% 135

Other funds holding AMGN

LMR Partners's AMGN Position: Q1 2026 in Review

LMR Partners sold out of Amgen (AMGN) in Q1 2026, closing a stake of 2 shares — an estimated $655 sold.

LMR Partners first reported a position in AMGN in Q4 2014 and held it in 29 quarters. The position peaked at $10.9M in Q4 2024. 3,127 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • LMR Partners reported no remaining Amgen position as of Q1 2026 after selling out during the quarter.
  • LMR Partners sold 2 Amgen shares in Q1 2026, an estimated $655.
  • LMR Partners first reported a position in Amgen in Q4 2014 and held it in 29 quarters.
  • LMR Partners's Amgen position peaked at $10.9M in Q4 2024.
  • 3,127 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.